A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma

Conclusions. Weekly paclitaxel at a dose of 60 mg/m2 in combination with carboplatin at an AUC of 5 is well tolerated and active in potentially platinum-sensitive recurrent ovarian and peritoneal carcinoma.